Latest News and Press Releases

CARLSBAD, Calif. and SHANGHAI, China, May 07, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), and co-development partner Newsoara today announce completion of a Phase 2 clinical trial...

CARLSBAD, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications,...

The combined company, Palisade Bio, Inc., is expected to commence trading on the Nasdaq Capital Market under the ticker symbol “PALI” on April 28, 2021 Concurrent $20.0 million private placement...

CARLSBAD, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. (“LBS” or "the Company"), a privately held company that recently entered into a definitive agreement for a reverse...

Video message details merger closing process following completion of the April 23 virtual Special Meeting as well as next planned milestones for the merged company to be renamed Palisade Bio As of...

Video messages urges Seneca stockholders to vote in support of Proposal #1, the reverse stock split, in order to approve the proposed transaction. Proposal 1 was favored by a wide margin by Seneca...

Video message explains the multiple benefits of the proposed merger and provides an overview of the substantial market opportunity for the combined company to be named Palisade Bio Seneca...

Combined company, to be named Palisade Bio, will be well-positioned to leverage its compelling therapeutics pipeline, strong cash position, and accomplished management and Board to maximize...

CARLSBAD, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. (“LBS”), a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca...

CARLSBAD, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. (“LBS”), a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca...